ESTRO 2025 - Abstract Book

S2134

Clinical - Urology

ESTRO 2025

Conclusion: Achieving an undetectable PSA level at six months post-curative RT+ADT is an independent predictor of improved BRFS and CRFS in PCa patients. Larger cohorts are needed for assessing the role of undetectable 6 months PSA level in DMFS.

Keywords: psa, undetectable, prostate

References: Kwak, L., Ravi, P., Armstrong, J. G., Beckendorf, V., Chin, J. L., D’Amico, A. V., Dearnaley, D. P., Di Stasi, S. M., Gilless en, S., Lukka, H., Mottet, N., Pommier, P., Seiferheld, W., Sydes, M. R., Tombal, B., Zapatero, A., Regan, M. M., Xie, W., & Sweeney, C. J. (2024). Prognostic impact of Prostate-Specific antigen at 6 months after radiotherapy in localized prostate cancer: an individual patient data analysis of randomized trials. Journal of Clinical Oncology , 42 (18), 2132 – 2138. https://doi.org/10.1200/jco.23.00762

4434

Poster Discussion Dosimetric Analysis of Urethral and Bladder Toxicities: Insights from the Prospective HypoFocal II Trial (DRKS00017570, ARO2020-01) Sophia L Bürkle 1,2 , Ilias Sachpazidis 3,2 , Simon Kirste 1,2 , Constantinos Zamboglou 1,2,4 , Dimos Baltas 3,2 , Anca-L. Grosu 1,2 , Simon KB Spohn 1,2 1 Department of Radiation Oncology, Medical Center Freiburg, University of Freiburg, Freiburg, Germany. 2 German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. 3 Division of Medical Physics, Department of Radiation Oncology, Medical Center Freiburg, University of Freiburg, Freiburg, Germany. 4 Department of Radiation Oncology, German Medical Institute (GMI), European University of Cyprus, Limassol, Cyprus